More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...

Johnson & Johnson, Eli Lilly, Sanofi and Bristol Myers Squibb are suing the federal government over the future of their 340B drug rebate plans. The lawsuits reflect rising tensions among drugmakers, ...

The 340B drug pricing program is complicated. A clinic leader and a hospital said that’s making it easy for there to be misunderstandings about if the savings are being passed onto the patient.

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

On April 18, 2024, the U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA) released a new Final Rule for its oft-criticized 340B Administrative ...

The 340B Drug Pricing Program helps poor states like Kentucky. Bigstock Senate Bill 14 in the ongoing Kentucky legislative session relates to the federal 340B Drug Pricing Program. This program ...

A federal court has sided with the U.S. Department of Health and Human Services (HHS), rejecting Johnson & Johnson’s (NYSE:JNJ) effort to reshape its participation in the 340B Drug Pricing Program.

Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the Health, Education, Labor and Pensions Committee appear to agree that ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...

The 340B drug discount program dates back to President George H.W. Bush, and it's a lifeline for rural Kansas hospitals and their patients. Topeka Capital-Journal file photo Kansas Sen. Jerry Moran ...